68 The FDA can approve specified forms of drug available for sale while in the U.S. according to clinical-trials final results that depend upon these types of surrogate steps rather then on immediate steps of the drug’s medical gain. Such as, FDA’s steering, described earlier mentioned, on how drug organizations can establish bioequivalence